Member Info for Peterrr

All good, management remuneration still heavily weighted to performance based equity, so not so much cash burn. Nothing unexpected in the accounts.

Unfortunately the Italian regulator has put a stop to that on anti trust grounds. Hopefully they can find a work around.

My bad. I was also adding in the biomass fermentation expansions in the US, which skewed it a lot. For precision I agree not much at scale in the US mainly pilot size. Not to say there are no other options, Perfect Day bought an Indian contract producer rather than build in the US or keep using Olon in Italy to bring down costs.

People are already consuming the products from precision fermentation globally , they just don't recognise it. Aijinmoto's turnover in this biotech area is 200b yen per year growing at 20% pa. But I take with a grain of salt the claim that Liberation labs has open access to unmet demand. Maybe I'm wrong but a quick google shows a number of other large plants at a similar stage of build.

Oak always assumes the top end of everything but if they are going to get £100m returned there is only £50m left for the year, the profit from which will be substantially eaten by the management fee.

They can't as the FSA timelines are completely inflexible and they can't afford a breach by just stopping work because they have filed a case.

Don't hold your breath. They didn't get anything worthwhile the last time they were up against them for misleading advertising and the firm was only asked to take more care, no injunction. This case was filed a month ago so hopefully won't have to wait too long for an outcome. Unfortunately I can't source the filing. UK is hopeless as most other countries there is public access to filings real time, so you have a better idea of the arguments.

Actually the old option holder Soligenix is a prime candidate for a Polb back door listed, in very poor financial health with but a bucket load of approved orphan drugs and completed phase 2s. It looks like they let the option laspse from lack of money rather than lack of potential.

Totally wrong, I'm still buying not selling. Management motivation is to get their first tranche of free shares and then grant themselves some more. I'll happily line up with their hurdles.

At least they saved money on the RNS draft, it is a cut and paste from the last lot that held the option last year.

Cavendish couldn't go below 17p.as management stock grant only realises if that can hold for 2 weeks and they will want to get their hands on them sooner rather than later when they are running down the cash.

Tide turn, successful injunction to stop frivolous legal claims, write off of credit card debt for this FY not as large as the accounts forecast, trading update showing the app is delivering increased engagement and revenue, a few more of the board buy in, staff reduction and offshoring beats budget again. CEO doesn't seem the type to report rubbish so at least updates should hopefully be able to be taken at face value. In my top drawer, but still adding a few on the drops.

I am a little more comfortable with the NAV as they have been probably supported in the context of a possible Fca review so audit and board would be on notice. However actual accounts may have to flag up post balance date events, so may not read as solid as this update with Graphcore bound to get a mention.

I have a concern about going private but mainly about lack of freedom. There are some heavy hitters amongst the iis so I don't think they will allow themselves to be shafted and will make the call, not management. I've had a buy in at 2.15 for a while, eventually hit, but it could easily go lower.

Ignoring the multinationals, nope. In bed with aijinmoto and you can't get much bigger in top line food tech. Loose change to them but they will do all they can to make it work as they have bought the dream and have the scientists to see it through if commercially viable. .

Note to self: Pay more attention to those who have been watching this for years and don't hang around for the divi...... Did flog a few for a few quid up and will average down almost risk free, but live and learn and try to do better next time with a bigger pot.

Don't worry Team. It is a time barred rotation flagged in 2021. Ex KPMG on the board which is likely why they got the gig.

We are all mushrooms here Wild, unless you have a particular steer from those Hedge Fund mates of yours to share.

Meatly is dog food which is the point I was making. That should be the first commercial product off the shelves. Sure for human stand alone food products bring in the food critics, but meatly and liberation labs won't be in that space for a while.

I don't any of the dogs attending meatly's launch are going to be turned down so we should be OK at least for that one. Same with the other food additive development such eggs to be used in mass production. Unless the food critics want to chow down on dog food.